Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 2Neuroblastoma 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 24Vincristine 20Carboplatin 18Doxorubicin 15Etoposide 14Melphalan 12Radiotherapy 11Filgrastim 11Cisplatin 11Magnetic Resonance Spectroscopy 10Isotretinoin 10Specimen Handling 9Peripheral Blood Stem Cell Transplantation 9dinutuximab 8Biopsy 8X-Rays 7Topotecan 7Temozolomide 7aldesleukin 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Busulfan 6sargramostim 5Irinotecan 5Vindesine 4Neoadjuvant Therapy 4Ipilimumab 4Ifosfamide 4Dacarbazine 43-Iodobenzylguanidine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroblastoma × iberdomide × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡